Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
LINDSAY, Ontario, 05 juin 2025 (GLOBE NEWSWIRE) -- Aujourd’hui, la Fondation des soins avancés en urgence coronarienne (ACT) s’est jointe à Hydro One Inc. (Hydro One) et à ses partenaires de l’école...
-
LINDSAY, Ontario, June 05, 2025 (GLOBE NEWSWIRE) -- Today, the Advanced Coronary Treatment (ACT) Foundation joined Hydro One Inc. (Hydro One) and partners at I.E. Weldon Secondary School in Lindsay...
-
New York, USA, June 05, 2025 (GLOBE NEWSWIRE) -- Global Antidote Market to Cross the USD 4 Billion Mark by 2032 | DelveInsight The antidote market is witnessing substantial growth, largely...
-
Continued commitment to reducing the number of opioid overdose deaths by expanding access, increasing awareness and educating the public about life-saving naloxone GAITHERSBURG, Md., June 05, 2025...
-
Teva outlines acceleration path into a leading biopharma companyInnovative medicines franchise on track to exceed $5 billion by 2030, led by AUSTEDO® (deutetrabenazine), AJOVY® (fremanezumab), UZEDY®...
-
First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior yearFirst Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior yearFirst Quarter 2025 Gross Margin...
-
CHARLOTTETOWN, Île-du-Prince-Édouard, 07 mai 2025 (GLOBE NEWSWIRE) -- La Fondation Advanced Coronary Treatment (ACT) s’est jointe au gouvernement de l’Île-du-Prince-Édouard (Î.-P.-É.) et à...
-
CHARLOTTETOWN, Prince Edward Island, May 07, 2025 (GLOBE NEWSWIRE) -- The Advanced Coronary Treatment (ACT) Foundation joined the Government of Prince Edward Island (PEI), and its partners at...
-
For an accessible version of this Press Release, please visit www.tevapharm.com On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth...
-
WINNIPEG, Manitoba, May 01, 2025 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced a maximum three-year agreement with a value of approximately $65 million to supply the...